A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

~42 mi. (München, Germany, +192 more cities)

Klinikum der Universität München Großhadern, +1 more facility

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~42 mi. (München, Germany, +226 more cities)

Klinikum Rechts der Isar ( Site 0300)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

~42 mi. (München, Germany, +147 more cities)

Klinikum der Universitaet in Muenchen ( Site 0446), +1 more facility

Cervical Adenocarcinoma, +2 more conditions

brachytherapy, +3 more drugs

chemotherapy, +2 more types

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~42 mi. (München, Germany, +199 more cities)

Klinikum rechts der Isar der Technischen Universitaet ( Site 0470)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~42 mi. (München, Germany, +207 more cities)

Klinikum der Universitaet Muenchen - Grosshadern ( Site 1000)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

~42 mi. (München, Germany, +163 more cities)

Klinikum der Universitaet Muenchen - Grosshadern ( Site 0548)

Bladder Urothelial Carcinoma

cystectomy, +2 more drugs

chemotherapy, +3 more types

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

~42 mi. (München, Germany, +131 more cities)

Klinikum Rechts der Isar der TU Muenchen ( Site 1200)

HER2 Negative

Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions

CAPOX regimen, +3 more drugs

chemotherapy, +2 more types

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

~42 mi. (München, Germany, +150 more cities)

Klinikum rechts der Isar der Technischen Universitaet ( Site 0409)

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

~42 mi. (München, Germany, +151 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

niraparib, +1 more drug

immunotherapy, +1 more type

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

~42 mi. (München, Germany, +144 more cities)

GSK Investigational Site

Endometrial Carcinoma

carboplatin, +3 more drugs

chemotherapy, +2 more types

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

~42 mi. (München, Germany, +170 more cities)

Novartis Investigative Site

ER Negative, +4 more biomarkers

Breast Carcinoma

alpelisib, +1 more drug

chemotherapy, +1 more type

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

~42 mi. (München, Germany, +165 more cities)

Haemato-Onkologie /ID# 221061

del(11)(q10), +27 more biomarkers

Myelofibrosis

navitoclax, +1 more drug

targeted therapy